Table 2.
Univariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS) of patients with DLBCL
| Variable | 5-year OS rate (%) | P value | 5-year PFS rate (%) | P value |
|---|---|---|---|---|
| Age (years) | < 0.01 | 0.02 | ||
| ≤ 60 | 66.7 | 54.7 | ||
| > 60 | 42.1 | 38.8 | ||
| Clinical stage | < 0.01 | < 0.01 | ||
| I–II | 68.2 | 61.7 | ||
| III–IV | 50.7 | 38.4 | ||
| B symptoms | 0.02 | < 0.01 | ||
| No | 63.8 | 54.2 | ||
| Yes | 48.7 | 38.7 | ||
| Spleen involvement | 0.01 | < 0.01 | ||
| No | 62.4 | 53.0 | ||
| Yes | 41.8 | 31.4 | ||
| IPI | < 0.01 | < 0.01 | ||
| < 3 | 64.4 | 55.6 | ||
| ≥ 3 | 41.9 | 29.6 | ||
| LDH (U/L) | < 0.01 | < 0.01 | ||
| ≤ 245 | 72.7 | 60.1 | ||
| > 245 | 46.2 | 39.0 | ||
| β2-MG (mg/L) | < 0.01 | 0.07 | ||
| ≤ 2.52 | 73.2 | 54.6 | ||
| > 2.52 | 42.2 | 35.7 | ||
| Rituximab | 0.04 | 0.20 | ||
| Without | 53.1 | 46.4 | ||
| With | 71.9 | 58.4 | ||
| First-line chemotherapy CR | < 0.01 | 0.04 | ||
| No | 49.1 | 45.9 | ||
| Yes | 72.2 | 57.2 | ||
| PD-L1 expression in tumor cells | 0.02 | 0.01 | ||
| Negative | 67.3 | 59.6 | ||
| Positive | 50.0 | 39.6 | ||
| PD-L1 expression in tumor microenvironment | 0.21 | 0.26 | ||
| Negative | 62.0 | 52.5 | ||
| Positive | 48.9 | 39.3 |
IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death-ligand 1